BNET Industries

Sanofi-Aventis

SNY is in the Pharma Industry

Market Cap:$101.1B
Last Fiscal Year Sales:$32.9B
  • Public
  • FR
Dow Jones Description

Sanofi-Aventis sees the future - where disease is in the past. Formed by a 2004 merger and headquartered in Paris, France, Sanofi-Aventis (NYSE: SNY (ADR) Euronext Paris: SAN) is the third-largest pharmaceutical maker in the world. The company researches, develops, manufactures, and markets prescription drugs. Its products include Allegra, Aprovel, Eloxatin, Lovenox, Nasacort, Plavix, Taxotere, and Tritace, among others. It has over 100 compounds in development, about 40 of which are in Phase II or III clinical trials. The company has annual revenue of about A28.5 billion and employs about 100,000 people. In March 2006 the company acquired almost 25% of Zentiva NV for approximately A430 million. In 2005 the company sold its interests in Wacker-Chemie.

Number of Employees 97,181
Contact Information

174 Ave De France

Paris

www.sanofi-aven...

(33) 153774000

NAICS Code Drugs and Druggists' Sundries Merchant Wholesalers: 424210

Recent Events

  • The Side Effect of Developing Obesity Drugs

    11/23/09 - Bond / Stock Rating - View Story

  • Drugmakers' Differences: Analyst's Toolkit

    11/18/09 - Financial Announcement - View Story

  • Deutsche Bank Initiates Coverage on Sanofi-Aventis SNY with a Buy

    11/16/09 - Bond / Stock Rating - View Story

  • Big Pharma Willing to Pay for Biotech Innovation

    11/15/09 - Joint Venture / Alliance - View Story

  • Sanofi-Aventis names Spek global operations head 37 mins ago

    11/02/09 - Mgmt. Change Entering - Vice President - View Story

  • Sanofi-Aventis Q3 Profit Rises; Lifts FY09 Adj. EPS Growth View; To Buy Laboratoire Oenobiol -...

    10/30/09 - Merger / Acquisition - View Story

  • UPDATE 3-Sanofi lifts forecast on swine flu vaccine

    10/30/09 - Financial Announcement - View Story

  • Sanofi-Aventis and Micromet to Develop New Tumour Antibody

    11/02/09 - Joint Venture / Alliance - View Story

  • Dyax Corp. Q3 2009 Earnings Call Transcript

    10/29/09 - Merger / Acquisition - View Story

  • Sanofi-Aventis's New JV Will Provide Entry into Chinas OTC Market

    10/27/09 - Product Announcement - View Story

  • Mexico pushing for homegrown swine flu vaccine

    10/24/09 - Planned Site Openings - View Story

  • Sanofi cozies up to Wellstat for $350M diabetes insulin pact

    10/22/09 - Joint Venture / Alliance - View Story

  • Sanofi-Aventis France (SASY.PA) Buys Wellstat Therapeutics Corporation's Type II Diabetes Drug PN2034 For Up To...

    10/21/09 - Merger / Acquisition - View Story

  • Wellstat Therapeutics and Sanofi-aventis Enter Agreement On Novel Therapy for Type II Diabetes

    10/21/09 - Joint Venture / Alliance - View Story

  • Notable Analyst Rating Changes 10/14: CSC, GSK, SNY, ABX, CNO, HOG, TEL Upgrade; VLO, JBLU,...

    10/14/09 - Bond / Stock Rating - View Story

  • Sanofi-Aventis France (SASY.PA) to Buy Dyax Corp. DYAX's Drug Development Partner, Fovea Pharmaceuticals

    10/13/09 - Merger / Acquisition - View Story

  • BRIEF-Credit Suisse raises targets on European pharma cos

    10/13/09 - Bond / Stock Rating - View Story

  • Sanofi to launch own generic version of Plavix

    10/05/09 - Product Announcement - View Story

  • Sanofi-Aventis Boosts Pipeline with In-Licensing Deals, Acqusitions

    10/06/09 - Merger / Acquisition - View Story

News & Analysis

collaboration and sanofi-aventis - All News and Analysis

advertisement
SNY $38.43 -1.03 (-2.61% )
Volume 611,244
Shares Outstanding 2.6B
Market Cap 101.1B
Year High 40.17
Year Low 24.59
Earnings Per Share 2.21
P/E Ratio 17.3891
Dividend 1.0639
Yield 2.7684
IndustryTop Rated
advertisement